相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Platinum Derivatives Effects on Anticancer Immune Response
Cedric Rebe et al.
BIOMOLECULES (2020)
Pembrolizumab versus chemotherapy for microsatellite instability-high/mismatch repair deficient metastatic colorectal cancer: The phase 3 KEYNOTE-177 Study
Kai-Keen Shiu et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
The PD-1/PD-L1-Checkpoint Restrains T cell Immunity in Tumor-Draining Lymph Nodes
Floris Dammeijer et al.
CANCER CELL (2020)
Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma
Thomas Powles et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
A Phase I Dose-Escalation Trial of BN-CV301, a Recombinant Poxviral Vaccine Targeting MUC1 and CEA with Costimulatory Molecules
Margaret E. Gatti-Mays et al.
CLINICAL CANCER RESEARCH (2019)
Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer
Michael J. Overman et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial
Manish R. Patel et al.
LANCET ONCOLOGY (2018)
PD-1/PD-L1 pathway: an adaptive immune resistance mechanism to immunogenic chemotherapy in colorectal cancer
Magalie Dosset et al.
ONCOIMMUNOLOGY (2018)
Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer A Randomized Clinical Trial
Alan P. Venook et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2017)
Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma
Bert H. O'Neil et al.
PLOS ONE (2017)
Analyses of the peripheral immunome following multiple administrations of avelumab, a human IgG1 anti-PD-L1 monoclonal antibody
Renee N. Donahue et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2017)
A phase II study of pembrolizumab in combination with mFOLFOX6 for patients with advanced colorectal cancer.
Safi Shanda et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Accumulation of MDSC and Th17 Cells in Patients with Metastatic Colorectal Cancer Predicts the Efficacy of a FOLFOX-Bevacizumab Drug Treatment Regimen
Emeric Limagne et al.
CANCER RESEARCH (2016)
Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade
Joseph L. Benci et al.
CELL (2016)
Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial
Howard L. Kaufman et al.
LANCET ONCOLOGY (2016)
Nivolumab ± ipilimumab in treatment (tx) of patients (pts) with metastatic colorectal cancer (mCRC) with and without high microsatellite instability (MSI-H): CheckMate-142 interim results.
Michael J. Overman et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Extended evaluation of a phase 1/2 trial on dosing, safety, immunogenicity, and overall survival after immunizations with an advanced-generation Ad5 [E1-, E2b-]-CEA(6D) vaccine in late-stage colorectal cancer
Joseph P. Balint et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2015)
Molecular Markers Identify Subtypes of Stage III Colon Cancer Associated With Patient Outcomes
Frank A. Sinicrope et al.
GASTROENTEROLOGY (2015)
Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group
Lieke H. J. Simkens et al.
LANCET (2015)
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
D. T. Le et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Adverse Immunoregulatory Effects of 5FU and CPT11 Chemotherapy on Myeloid-Derived Suppressor Cells and Colorectal Cancer Outcomes
Julia Kanterman et al.
CANCER RESEARCH (2014)
Activated Lymphocyte Recruitment Into the Tumor Microenvironment Following Preoperative Sipuleucel-T for Localized Prostate Cancer
Lawrence Fong et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2014)
Immunogenic Cell Death in Cancer Therapy
Guido Kroemer et al.
ANNUAL REVIEW OF IMMUNOLOGY, VOL 31 (2013)
Novel adenoviral vector induces T-cell responses despite anti-adenoviral neutralizing antibodies in colorectal cancer patients
Michael A. Morse et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2013)
Phase I study of intraprostatic vaccine administration in men with locally recurrent or progressive prostate cancer
James L. Gulley et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2013)
The role of soluble CD40L in immunosuppression
Jeffrey Schlom et al.
ONCOIMMUNOLOGY (2013)
Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer
Julie R. Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer
Suzanne L. Topalian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
An Ad5[E1-, E2b-]-HER2/neu vector induces immune responses and inhibits HER2/neu expressing tumor progression in Ad5 immune mice
E. S. Gabitzsch et al.
CANCER GENE THERAPY (2011)
Induction and comparison of SIV immunity in Ad5 naive and Ad5 immune non-human primates using an Ad5 [El-, E2b-] based vaccine
Elizabeth S. Gabitzsch et al.
VACCINE (2011)
Anti-tumor immunotherapy despite immunity to adenovirus using a novel adenoviral vector Ad5 [E1-, E2b-]-CEA
Elizabeth S. Gabitzsch et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2010)
The T-box transcription factor Brachyury promotes epithelial-mesenchymal transition in human tumor cells
Romaine I. Fernando et al.
JOURNAL OF CLINICAL INVESTIGATION (2010)
Phase II Study of the Anti-Cytotoxic T-Lymphocyte-Associated Antigen 4 Monoclonal Antibody, Tremelimumab, in Patients With Refractory Metastatic Colorectal Cancer
Ki Y. Chung et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Immunogenic death of colon cancer cells treated with oxaliplatin
A. Tesniere et al.
ONCOGENE (2010)
The basics of epithelial-mesenchymal transition
Raghu Kalluri et al.
JOURNAL OF CLINICAL INVESTIGATION (2009)
Bevacizumab Beyond First Progression Is Associated With Prolonged Overall Survival in Metastatic Colorectal Cancer: Results From a Large Observational Cohort Study (BRiTE)
Axel Grothey et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Immunological aspects of cancer chemotherapy
Laurence Zitvogel et al.
NATURE REVIEWS IMMUNOLOGY (2008)
The human T-box mesodermal transcription factor Brachyury is a candidate target for T-cell-mediated cancer immunotherapy
Claudia Palena et al.
CLINICAL CANCER RESEARCH (2007)
Mucins in cancer: Protection and control of the cell surface
MA Hollingsworth et al.
NATURE REVIEWS CANCER (2004)
Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis
J Yang et al.
CELL (2004)
A 'modified de Gramont' regimen of fluorouracil, alone and with oxaliplatin, for advanced colorectal cancer
SL Cheeseman et al.
BRITISH JOURNAL OF CANCER (2002)
分享论文
